These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27834087)

  • 21. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.
    Kimmick GG; Peterson BL; Kornblith AB; Mandelblatt J; Johnson JL; Wheeler J; Heinze R; Cohen HJ; Muss HB
    J Clin Oncol; 2005 Apr; 23(10):2201-7. PubMed ID: 15800312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
    Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
    J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barriers to clinical trial recruitment in head and neck cancer.
    Haddad RI; Chan AT; Vermorken JB
    Oral Oncol; 2015 Mar; 51(3):203-11. PubMed ID: 25593017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.
    Dew A; Khan S; Babinski C; Michel N; Heffernan M; Stephan S; Jordan N; Jovanovic B; Carney P; Bergan R
    Clin Trials; 2013 Apr; 10(2):292-9. PubMed ID: 23321266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
    Sateren WB; Trimble EL; Abrams J; Brawley O; Breen N; Ford L; McCabe M; Kaplan R; Smith M; Ungerleider R; Christian MC
    J Clin Oncol; 2002 Apr; 20(8):2109-17. PubMed ID: 11956272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design-phase prediction of potential cancer clinical trial accrual success using a research data mart.
    London JW; Balestrucci L; Chatterjee D; Zhan T
    J Am Med Inform Assoc; 2013 Dec; 20(e2):e260-6. PubMed ID: 23851466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crossover is not associated with faster trial accrual.
    Chen EY; Prasad V
    Ann Oncol; 2018 Mar; 29(3):776-777. PubMed ID: 29267893
    [No Abstract]   [Full Text] [Related]  

  • 28. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study.
    Carter RE; Sonne SC; Brady KT
    BMC Med Res Methodol; 2005 Mar; 5():11. PubMed ID: 15796782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing accrual in cancer clinical trials with a focus on minority enrollment: The William Beaumont Hospital Community Clinical Oncology Program Experience.
    Vicini F; Nancarrow-Tull J; Shah C; Chmielewski G; Fakhouri M; Sitarek SA; Feczko CT; Brzozowski C; Felten DL
    Cancer; 2011 Oct; 117(20):4764-71. PubMed ID: 21455995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors.
    Jiang Y; Simon S; Mayo MS; Gajewski BJ
    Stat Med; 2015 Feb; 34(4):613-29. PubMed ID: 25376910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer.
    Kaas R; Hart AA; Rutgers EJ
    Breast; 2005 Aug; 14(4):310-6. PubMed ID: 16085238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of patient accrual rates in clinical trials based on routine data from hospital information systems.
    Dugas M; Amler S; Lange M; Gerss J; Breil B; Köpcke W
    Methods Inf Med; 2009; 48(3):263-6. PubMed ID: 19387510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations.
    Gerber DE; Lakoduk AM; Priddy LL; Yan J; Xie XJ
    Oncologist; 2015 Jun; 20(6):674-82. PubMed ID: 26018661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-stage plans for patient accrual in phase II cancer clinical trials.
    Lee YJ; Staquet M; Simon R; Catane R; Muggia F
    Cancer Treat Rep; 1979; 63(11-12):1721-6. PubMed ID: 526910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic cancer clinical trials and accrual in the United States.
    Hoos WA; James PM; Rahib L; Talley AW; Fleshman JM; Matrisian LM
    J Clin Oncol; 2013 Sep; 31(27):3432-8. PubMed ID: 23960185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accrual Index: A Real-Time Measure of the Timeliness of Clinical Study Enrollment.
    Corregano L; Bastert K; Correa da Rosa J; Kost RG
    Clin Transl Sci; 2015 Dec; 8(6):655-61. PubMed ID: 26573223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland.
    Kearns C; Feighery R; Mc Caffrey J; Higgins M; Smith M; Murphy V; O'Reilly S; Horgan AM; Walshe J; McDermott R; Morris PG; Keane M; Martin M; Murphy C; Duffy K; Mihai A; Armstrong J; O'Donnell DM; Gallagher WM; Kelly CM; Kelly CM
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of crowdsourcing for cancer clinical trial development.
    Leiter A; Sablinski T; Diefenbach M; Foster M; Greenberg A; Holland J; Oh WK; Galsky MD
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.
    Singletary E; Lieberman R; Atkinson N; Sneige N; Sahin A; Tolley S; Colchin M; Bevers T; Stelling C; Fornage B; Fritsche H; Hittelman W; Kelloff G; Lippman SM
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1087-90. PubMed ID: 11045792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.